May 18, 2017 / 10:39 AM / 2 months ago

BRIEF-Obseva SA says it intends to advance OBE022 into Phase 2A proof-of-concept clinical trial in second half of 2017

1 Min Read

May 18 (Reuters) - Obseva SA

* Says intends to advance obe022 into a Phase 2A proof-of-concept clinical trial in second half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below